emergency

Ulipristal acetate (CDB-2914) is an orally bioavailable selective progesterone receptor modulator with anti-progesterone activity. It binds to the progesterone receptor (PR), inhibiting PR-mediated gene expression and interfering with progesterone activity in the reproductive system, potentially suppressing the growth of uterine leiomyomatosis. Additionally, ulipristal can be used as emergency contraception by inhibiting or delaying ovulation and affecting endometrial tissue.

Ulipristal is a selective SPRM for emergency contraception after an unprotected intercourse or contraceptive failure.

Mivacurium dichloride (Mivacurium chloride) is a non-depolarising, rapid neuromuscular blocker of short duration, used therefore as anesthetic, to provide skeletal muscle relaxation in minor surgical operations, in emergency surgical procedures of short to intermediate duration and during intubation of the trachea.

Bamlanivimab, an Anti-Human SARS-CoV-2 monoclonal antibody (mAb), was the first of its kind to receive Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) in November 2020 for COVID-19 treatment. However, its authorization was withdrawn in April 2021 due to emerging SARS-CoV-2 variants resistant to the antibody [1].